Compare AMGN & SAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMGN | SAP |
|---|---|---|
| Founded | 1980 | 1972 |
| Country | United States | Germany |
| Employees | N/A | 100000 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 188.7B | 202.5B |
| IPO Year | 2002 | N/A |
| Metric | AMGN | SAP |
|---|---|---|
| Price | $355.20 | $164.18 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 19 | 6 |
| Target Price | ★ $351.05 | $288.00 |
| AVG Volume (30 Days) | 2.3M | ★ 3.0M |
| Earning Date | 04-30-2026 | 04-23-2026 |
| Dividend Yield | ★ 2.98% | 1.12% |
| EPS Growth | ★ 88.23 | N/A |
| EPS | ★ 3.34 | N/A |
| Revenue | ★ $25,424,000,000.00 | N/A |
| Revenue This Year | $5.00 | $10.28 |
| Revenue Next Year | $2.45 | $11.76 |
| P/E Ratio | $106.09 | ★ $28.01 |
| Revenue Growth | ★ 8.83 | N/A |
| 52 Week Low | $269.77 | $158.58 |
| 52 Week High | $391.29 | $313.28 |
| Indicator | AMGN | SAP |
|---|---|---|
| Relative Strength Index (RSI) | 60.63 | 38.78 |
| Support Level | $334.95 | $161.25 |
| Resistance Level | $356.53 | $182.94 |
| Average True Range (ATR) | 8.10 | 5.09 |
| MACD | 2.22 | -2.22 |
| Stochastic Oscillator | 86.70 | 10.01 |
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Founded in Germany in 1972 by former IBM employees, SAP is the world's largest provider of enterprise application software. Known as the leader in enterprise resource planning software, SAP's portfolio also includes software for supply chain management, procurement, travel and expense management, and customer relationship management, among others. The company operates in more than 180 countries and has more than 400,000 customers, approximately 80% of which are small to medium-size enterprises.